Updated on 24 October 2013
Opportunities may also lie in emerging countries, such as China, Brazil and APAC. When the rest of the economy was suffering from budget cuts and slash downs, most companies witnessed massive growth in APAC and rest of world countries. By increasing their direct sales force and acquiring distributors in these countries, companies have been able to successfully reap business.
Governments in several APAC countries are setting up favourable guidelines for growth of the hospital sector, such as investing in and improving services for the poor from state hospitals and public private-partnerships (PPPs). Private hospitals are also growing by virtue of government policies. For example, China allowed 100 percent foreign direct investment in the private hospital industry. This will positively impact the purchasing power and result in an increase in test volumes, leading to better accessibility.
"The future of pathology aims at collaborating with clinical next-generation sequencing to be able to provide a combination of pathology and genomic information," concludes Mr Ravishankar. "The tremendous growth in gene expression, micro RNA (miRNA) profiling and genotyping studies on formalin-fixed paraffin-embedded (FFPE) will drive the demand for improved upstream processes. Vendors of FFPE sample prep solutions must understand the current customer trends and future needs to capitalize on the expanding opportunities driven by clinical application of advanced genomic platforms."